Financial reports
ARS
2023 FY
Annual report to shareholders
4 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
4 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Departure of Directors or Certain Officers
10 Apr 24
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
19 Mar 24
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
13 Nov 23
8-K
Departure of Directors or Certain Officers
5 Sep 23
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
14 Aug 23
8-K
DiaMedica Therapeutics Announces $37.5 Million Private Placement
21 Jun 23
8-K
Regulation FD Disclosure
21 Jun 23
8-K
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
21 Jun 23
8-K
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
30 May 23
8-K
Regulation FD Disclosure
22 May 23
Registration and prospectus
S-3
Shelf registration
21 Mar 24
424B3
Prospectus supplement
10 Jul 23
S-3
Shelf registration
30 Jun 23
D
$37.54 mm in equity, sold $37.54 mm, 34 investors
27 Jun 23
D
$750.00 k in equity, sold $750.00 k, 1 investor
18 Apr 23
S-8
Registration of securities for employees
11 Aug 22
S-8
Registration of securities for employees
14 Mar 22
424B3
Prospectus supplement
15 Oct 21
D
$30M in equity, sold $30M, 10 investors
6 Oct 21
S-3
Shelf registration
5 Oct 21
Proxies
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 23
DEF 14A
Definitive proxy
4 Apr 23
PRE 14A
Preliminary proxy
17 Mar 23
DEFA14A
Additional proxy soliciting materials
5 Apr 22
DEF 14A
Definitive proxy
5 Apr 22
DEFA14A
Additional proxy soliciting materials
3 Jun 21
DEF 14A
Definitive proxy
3 Jun 21
DEFA14A
Additional proxy soliciting materials
20 Apr 20
Other
EFFECT
Notice of effectiveness
10 Apr 24
EFFECT
Notice of effectiveness
10 Jul 23
CORRESP
Correspondence with SEC
5 Jul 23
UPLOAD
Letter from SEC
5 Jul 23
CT ORDER
Confidential treatment order
22 Dec 21
EFFECT
Notice of effectiveness
15 Oct 21
CORRESP
Correspondence with SEC
12 Oct 21
UPLOAD
Letter from SEC
12 Oct 21
EFFECT
Notice of effectiveness
5 May 21
CORRESP
Correspondence with SEC
3 May 21
Ownership
4
Masuoka K. Lorianne
23 Jan 24
3
Masuoka K. Lorianne
23 Jan 24
4
Charles Pauling Semba
2 Jan 24
4
Richard Kuntz
2 Jan 24
4
Richard D. Pilnik
2 Jan 24
4
James T. Parsons
2 Jan 24
4
Randall Michael Giuffre
2 Jan 24
4
David J. Wambeke
16 Nov 23
SC 13G/A
TomEnterprise AB
27 Jun 23
SC 13G/A
TRILL AB
27 Jun 23